Triple-Neg Breast Cancer – GeneLit

Development of a novel BRCAness score that predicts response to PARP inhibitors.
Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, Yamamoto S, Narui K, Chishima T, Ishikawa T, Endo I, Takabe K.
Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.

PMID: 36371386
PubMed abstract

Free Full Text

Development of a novel BRCAness score that predicts response to PARP inhibitors.
Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, Yamamoto S, Narui K, Chishima T, Ishikawa T, Endo I, Takabe K.
Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.

PMID: 36371386
PubMed abstract

Free Full Text

Reproductive risk factors associated with breast cancer in young women by molecular subtype.
Ruddy KJ, Vierkant RA, Jahan N, Higgins A, Partridge A, Larson N, Radisky DC, Couch F, Olson J, Sherman ME.
Breast. 2022 Nov 9:S0960-9776(22)00187-4. doi: 10.1016/j.breast.2022.11.004. Epub ahead of print.

Free Full Text

Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.

PMID: 36307613
PubMed abstract

Free Full Text

Adolescent Triple-negative Breast Cancer with Germline Pathogenic Variants in both BRCA1 and TP53 Genes: A Case Report.
Chen D, Yuan M, Zhang Y, Zhang C, Wan D.
Front Oncol. 2022 Oct 26;12:970641. doi: 10.3389/fonc.2022.970641.

Case report
Free Full Text

Deciding on the best pharmacotherapy for advanced triple-negative breast cancer: expert guidance.
Corvaja C, Taurelli Salimbeni B, Nicolò E, Puglisi F, Curigliano G.
Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2139176. Epub ahead of print.

PMID: 36268855
PubMed abstract

Commentary
Free Full Text

Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
Breast. 2022 Oct 18:S0960-9776(22)00174-6. doi: 10.1016/j.breast.2022.10.009. Epub ahead of print.

Free Full Text

Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C, Cui J, Peng Z, Qian K, Wu R, Cheng Y, Yin W.
Eur J Med Res. 2022 Oct 15;27(1):201. doi: 10.1186/s40001-022-00839-0.

PMID: 36242046
PubMed abstract

Meta-Analysis
Free Full Text

CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer.
Xie XF, Wu NQ, Wu JF, Zhang GL, Guo JF, Chen XL, Du CW.
Cancer Lett. 2022 Oct 6:215944. doi: 10.1016/j.canlet.2022.215944. Epub ahead of print.

Emerging Targeted Therapies for Early Breast Cancer.
Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM.
Drugs. 2022 Oct 7. doi: 10.1007/s40265-022-01781-5. Epub ahead of print.

Review